Shots:

• The approval is based on five P-III studies of SELECT program- assessing Rinvoq in ~4-400 patients- including in Brazil
• The studies resulted in meeting its 1EPs & 2EPs. In SELECT COMPARE study- @12wks- 29% of patients receiving Rinvoq + MTX (methotrexate) achieved remission assessed by the DAS28 - PCR index
• Rinvoq (PO- qd) is JAK inhibitor- indicated to treat active- moderate to severe RA- who did not respond adequately or who were intolerant to one or more DMARD

Click here ­to­ read full press release/ article 

Ref: PRNewswire | Image:abbvie